Improving the management of inflammatory and autoimmune diseases has been a dream that seems to be happening slowly but surely in the past years. The improvement has gained energy and speed in 2015. The advancement in treatments has been demonstrated on several inflammatory and autoimmune diseases, including psoriatic arthritis, rheumatoid arthritis (RA), Crohn’s disease, systemic lupus erythematosus (SLE) and many other autoimmune diseases.
In January 2015, the U.S. Food and Drug Administration (approved Interleukin 17 inhibitor drug Cosentyx® (Secukinumab) developed by Novartis (NVS). The drug is also demonstrating efficacy . . .